

Anticonvulsant Activity of Methanol Stem Bark Extract of *Securinega Virosa* (Eupobiaceae) in Mice.

¹Tanko, Y., ¹Eze, E. D. ¹Jimoh, A., ¹Yusuf, M., ¹Mohammed, K. A., ³Balarabe, F.,
²M. G. Magaji And ¹Mohammed, A.

¹Department of Human Physiology, Faculty of Medicine, Ahmadu Bello University, Zaria, Nigeria.

²Department of Pharmacology and Therapeutics, Ahmadu Bello University, Zaria, Nigeria

³Department of Nursing Sciences, Faculty of Medicine, Ahmadu Bello University, Zaria, Nigeria

Abstract: The anticonvulsant property of methanol stem bark extract of *Securinega virosa* was evaluated in Pentylentetrazole and 4-aminopyridine-induced seizure in mice. To achieve this aim twenty five animals were grouped into five groups of (n=5) each. Group I served as a negative control and receive distilled water, Group II to IV were administered with 12.5, 25.0 and 50mg/kg bw of the extract while Group V received standard drug Valproic acid 200mg/kg b w respectively intraperitoneally. The onset of convulsion and mortality were determined. The results of this study showed that stem bark extract of *Securinega virosa* offered protections (80 and 20%) at the doses administered (12.5 and 25mg/kg b w) and (20%) at a tested dose (50mg/kg b w) in Pentylentetrazole and 4-aminopyridine induced seizure, implying that 12.5mg/kg bw exhibited a higher protective activity. This suggests that then plant extract possesses bioactive constituents that may be beneficial in the management of epilepsy and lend credence to the traditional use of this plant in management of epilepsy.

Key words: Convulsion, Epilepsy, Mice, Pentylentetrazole, *Securinega virosa*, seizure

I. Introduction

Convulsion is a pathological body condition characterized by abdominal, violent and uncontrolled spasmodic contractions and relaxations of the voluntary muscles. Convulsion is often interchangeably with seizure, although there are many types of seizure, some of which have subtle or mild symptoms instead of convulsions. Epilepsy is the second most common neurological disorder after stroke, effecting at least 50 million persons worldwide and approximately 40% of them are women [1]. Epilepsy shows a prevalence rate in 1-2% of the world population [2]. Seizures of all types are caused by disorganized and sudden electrical activity in the brain [3]. Epilepsy is a chronic and often progressive disorder characterized by the periodic and unpredictable occurrence of epileptic seizures, i.e., involuntary contraction of striated muscle repeatedly. Convulsion arises due to sudden excessive and rapid discharge of cerebral neurons in the grey matter of the brain [4]. There is a pressing need for new anticonvulsants for children and adults with medically refractory epilepsy [5]. The strategies for the development of antiepileptic drugs have heavily relied on the basic premise that epilepsies are due to an imbalance between excitatory and inhibitory transmission in the brain [6]. Epileptic drug therapy in most patients is based on experimental seizure classification, because diversity causes the seizure drugs to be less specific for each of these effects. About 1% of people are born with epilepsy and approximately 10% of the population will experience a seizure. Although, by standard treatment in 80% of the seizure can be controlled, nevertheless the millions of people have uncontrolled epilepsy [7]. Plants have been major sources of medicine and plant secondary metabolite has been attributed for most plants' therapeutic activities [8]. *Securinega virosa* is one of the great African medicinal plants described as a true "cure all", of which all parts are used as remedies, particularly the root [9] - [10]. In Nigeria, it is found in virtually all parts of the country. In many parts of Africa including the north Eastern Nigeria, the root and leafy twig decoctions are used for the treatment of epilepsy. It is a dense, low branching, many branched shrub, sometimes a small spreading tree up to about 6 m high, although, more commonly 2 to 3 m, evergreen or deciduous [9]. It is widely distributed throughout tropical Africa, also in India, Malaya, China and Australia [11]. The root is used in many parts of Africa in the treatment of fever, body pain, stomach ache rheumatism, diarrhoea, pneumonia and epilepsy [9][12]. Hence, this study was aimed at assessing the anticonvulsant activity of methanol stem bark extract of *Securinega virosa* in Pentylentetrazole and 4-aminopyridine-induced seizure in mice

II. Materials And Methods

2.1 Location and duration of the study

This study was carried out at the Animal House of the Department of Human Physiology, Faculty of Medicine, Ahmadu Bello University, and Zaria Kaduna, Nigeria in the month of February, 2008.

2.2 Drugs

These include: Pentylenetetrazole (9.0 mg/kg), 4-aminopyridine (1.5 mg/kg), Valproic acid (200 mg/kg) and phenobarbitone (20 mg/kg). Other chemicals used were of analytical grade.

2.3 Collection of plant material

The whole plant, *Securinega virosa* was collected from Basawa town, Sabon gari Local Government Area, zaria Kaduna State in the month of January, 2007. The plant was identified and authenticated by Mallam Umar Gallah of the Herbarium section of the Department of Biological Sciences, Ahmadu Bello University, zaria where a voucher specimen number (918) was deposited.

2.4 Extraction of plant material

The stem bark of the plant was cleaned and the bark removed separately. They were air dried under shade and then milled into coarse powder of 100 g. The powdered stem bark was macerated in 500 ml of methanol with occasional shaking to obtain the dried extract of 8.5%. The extract was stored in a desiccator until it was reconstituted in an appropriate volume.

2.5 Animal management and care

Swiss albino mice (20 - 30 g) of either sex were obtained from the Animal house facility of the Department of Pharmacology and Clinical Pharmacy, Ahmadu Bello University, Zaria, Nigeria. They were housed in standard cages and kept under controlled room temperature in a 12 h light-dark cycle. The animals were fed on standard feeds (Vital feeds, Jos Nigeria) and allowed access to water *ad libitum*.

III. Experimental Procedures

3.1 4-aminopyridine -induced Seizure in mice

The method described by Yamaguchi and Rogawski (1992) [13] was employed. A total of twenty five (25) mice were used in this study, Group I received 10ml of distilled water Group II received 12.5 mg/kg b w of *S.virosa* ip, Group III received 25 mg/kg b w of *S. virosa* ip, Group IV received 50 mg/kg b w of *S. virosa* ip and Group V received 30 mg/kg b w of phenobarbitone (standard drug). Thirty (30) minutes after the administration with the above doses of plant extract of *S. virosa*, convulsions was induced with using 4-aminopyridine (1.5 mg/kg b w) subcutaneously and were observed over a period of 30 minutes. Absence of an episode of clonic spasm of at least 5 seconds duration indicated the extract's ability to abolish the effect of 4-aminopyridine on seizure threshold and mortality was observed and recorded.

3.2 Pentylenetetrazole-induced Seizure in mice

In this study, twenty five (25) mice were assigned into different groups as follows: Group I received 0 ml of distilled water, Group II received 12.5 mg/kg b w of *S.virosa* ip, Group III received 25 mg/kg b w of *S. virosa* ip, Group IV received 50 mg/kg b w of *S. virosa* ip, Group V received 200 mg/kg b w of Valproic acid (standard drug). Thirty (30) minutes after treatment, the animals induced with pentylenetetrazole (9.0 mg/kg b w). The onsets of seizure and mortality rate were evaluated [14].

3.3 Statistical Analysis

Data obtained were statistically analyzed using one-way analysis of variance (ANOVA) with Tukey's multiple comparison post hoc tests to compare the level of significance between control and experimental groups. All statistical analysis was evaluated using SPSS version 17.0 software. The values of $p < 0.05$ were considered as significant [15].

IV. Results And Discussion

4.1 Effect of Methanol stem bark extract of *Securinega virosa* on 4-aminopyridine-induced seizure in mice

"TABLE" 1 showed that the plant extract exhibited 20% protection against the 4-aminopyridine-induced seizure at a dose of 50 mg/kg b w and significantly ($p < 0.05$) prolonged the onset of seizure from 10 ± 1.10 mins 14.7 ± 4.40 mins in mice when compared. However, the extract at dose levels of 12.5 and 25 mg/kg b w did not protect the animals against 4-aminopyridine -induced seizure.

4.2 Effect of Methanol stem bark extract of *Securinega virosa* on Pentylenetetrazole -induced seizure in mice

"TABLE" 2 showed the control group animal exhibited generalized myoclonic body twitches, generalized body seizure with loss of right reflex with tonic forelimb extension and loss in the pentylenetetrazole-induced seizure with a mean of 10.0 ± 3.1 (mins) and offered 0% protection to the animals with 60% mortality rate recorded. The study revealed that the 12.5 and 50 mg/kg b w of *Securinega virosa*

significantly ($P < 0.05$) prolong the onset of pentylenetetrazole-induced seizure from 10.0 ± 3.1 (mins) to 14.0 ± 0.0 and 16.30 ± 5.9 and offered 80 and 0 % protection and 20 and 0% mortality respectively compared with the control (Table 2). The extract at dose level of 25 mg/kg bw did not protect the animals against pentylenetetrazole-induced seizure and 100% mortality recorded.

Table 1: Effect of Methanol stem bark extract of *Securinega virosa* on 4-aminopyridine-induced seizure in mice

Treatment given	Mean onset of seizure (mins)	Percentage protection (%)	Mortality (%)
Control+distilled water	10.0 ± 1.10	0.0	0.0
12.5 mg/kg b w	8.6 ± 0.70^{ns}	0.0	0.0
25 mg/kg b w	10.8 ± 3.10^{ns}	0.0	0.0
50 mg/kg b w	14.7 ± 4.40^a	20	80
20 mg/kg b w of Phenobarbitone	—	100	0.0

^a $p < 0.05$ is statistically significant when compared to control group, while ns= not significant when compared to the control group

Table 2: Effect of Methanol stem bark extract of *Securinega virosa* on Pentylenetetrazole -induced seizure in mice

Treatment given	Mean onset of seizure (mins)	Percentage protection (%)	Mortality (%)
Control + distilled water	10.0 ± 3.10	0.0	60
12.5 mg/kg b w	14.0 ± 0.0^a	80	20
25 mg/kg b w	7.3 ± 2.7^{ns}	20	20
50 mg/kg b w	16.3 ± 5.9^a	0.0	100
200 mg/kg b w of Valproic acid	—	100	0.0

^a $p < 0.05$ is statistically significant when compared to control group, while ns= not significant when compared to the control group

V. Discussion

The 4-aminopyridine and Pentylenetetrazole (PTZ) models are widely believed to be predictive of activity in common form of human epilepsy [16] - [17]. The anticonvulsant activities of stem bark extract of *Securinega virosa* were investigated by the pentylenetetrazole- and 4-aminopyridine-induced seizure models. Prevention of seizures induced by pentylenetetrazole in laboratory animals is the most commonly used preliminary screening test for characterizing potential anticonvulsant drugs [18]. Generally, compounds with anticonvulsant activity in the petitmal epilepsy are effective in pentylenetetrazole-induced seizure model [19]. The study showed that the extract at 12.5 and 25 mg/kg b w did not protect the animals against PTZ-induced seizure. However, the extract at dose level of 50 mg/kg b w offered 20% protection and significantly prolonged the onset of seizure in mice when compared to the control group. Anticonvulsant activity in pentylenetetrazole test identifies compounds that can raise seizure threshold in the brain [20]. Pentylenetetrazole has been shown to interact with GABA neurotransmitters and the GABA receptor complex. Antagonism of PTZ-induced seizures suggests effects on GABA-ergic neurotransmission. The anticonvulsant activity of the extract against PTZ-induced seizures suggests that the extract may be effective in the therapy of absence or myoclonic seizures by modifying excitatory and inhibitory neurotransmission through effects on voltage gated ion channels, GABA (A) receptors and glutamate mediated excitatory neurotransmission [21]. 4-Aminopyridine is a known potassium channel blocker [13]. The study revealed that the extract exhibited 20% protection against the 4-aminopyridine-induced seizure at a dose of 50 mg/kg b w and prolonged the onset of seizure from in mice when compared. However, the extract at dose levels of 12.5 and 25 mg/kg b w did not protect the animals against 4-aminopyridine -induced seizure. The absence of anticonvulsant activity against 4-AP induced seizures suggests that the extract may not have activity against potassium channels.

VI. Conclusion

From the above study it was concluded that, the methanol stem bark extract of *Securinega virosa* exhibits anticonvulsant activity and the probable mode of action may be due to GABA aminergic mediation and glutamate mediated excitatory neurotransmission.

References

- [1] M.L.Scheuer and T. A. Pedley, The evaluation and treatment of seizures. *New Engl J Med.*; (323), 1990, 1468–74.
- [2] P. Kamboj, I. Singh, N. Mahadevan and G. Chaudhary, Anticonvulsants from nature. *Phcog Rev.*; 3(5), 2009, 108–17.
- [3] C. G. Goet and E. J. Pappert, Text book of clinical Neurology 2nd ed. (Philadelphia, pa: Saunders, 2003).
- [4] K. Suresh, M. Reecha, B. Gundeep, J. Anupam and S. Anupam, Plants and Plant Products with Potential Anticonvulsant Activity – A Review. *Pharmacognosy Communications* Volume (2), 2012, Issue (1) Suppl.
- [5] X. Lin, R. Nicholas, Y. Xiao-Feng, X. Z. Hai, L.T. Liu, M.R. Steven, E.W. Aryan, W. Michael and A.Y. Kelvin A. Y, Leptin inhibits 4-aminopyridine- and pentylenetetrazole-induced seizures and AMPAR-mediated synaptic transmission in rodents. *Journal of Clinical Investigatio*, .118 (1), 2008, 272–280.
- [6] A. Atif, J.A. Farhan, K.P. Krishna, and V. Divya, Amiloride protects against pentylenetetrazole-induced kindling in mice, *British Journal of Pharmacology*; 145(7), 2005, 880–884.
- [7] J. Engel, A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. *Epilepsia*, (42), 2001, 796-803.
- [8] P.O. Fabeku, *Traditional Medicine: the art, ways and practice*. In: Odugbemi, T, editor, *Outlines and Pictures of Medicinal Plants from Nigeria*, (University of Lagos Pres, 2006) 13-24.
- [9] J.D. Neuwinger, Translated from by Porter A. African ethnobotany poison and drugs, (Chapman and Hall, Weinheim, 1996) pp. 495-499.
- [10] Y. Tanko, M.A. Okasha, G. M. Magaji, M. Yerima, A.H. Yaro, M.I.A. Saleh and A. Mohammed, Anti-diabetic properties of *Securinega virosa* (Euphorbiaceae) leaf extract. *African Journal of Biotechnology*, Vol. 7 (1), 2008, pp. 022-024.
- [11] J. M. Dalziel, *The useful plants of West Tropical Africa*, (Watmonghs, Idle, London, 1936) pp. 354-355.
- [12] M. G. Magaji, J.A. Anuka, I. Abdu-Aguye, A.H. Yaro and I.M. Hussaini, Preliminary studies on anti-inflammatory and analgesic activities of *Securinega virosa* (Euphorbiaceae) in experimental animal models. *Journal of Medicinal Plants Research* Vol. 2(2), 2008, pp. 039-044.
- [13] S.I. Yamaguchi and M.A. Rogawski, Effects of 4-aminopyridine-induced seizure in mice. *Epilepsy Research* (11), 1992, 9-16.
- [14] H.M. Salahdeen and O.K. Yemitan, Neuropharmacological effects of aqueous leaf extract of *Bryophyllum pinnatum* in mice, *African J Bio Med Res*, 9, 2006, 101-07.
- [15] R.C. Duncan, R.G. Knapp and M.C. Miller, *Test of hypothesis in population means*. In: *Introductory Biostatistics for the health sciences*, (John Wiley and Sons Inc. NY pp, 1977) 71-96.
- [16] A.D. Wickenden, Potassium channels as antiepileptic drug targets. *Neuropharmacology*, 43, 2002, 1055-1060.
- [17] B. Maiha, M. G. Magaji, A.H. Yaro, A.H. Hamza, S.T., Ahmed and R.A. Magaji, **Anticonvulsant** studies on *Cochlospermum tinctorium* and *Paullinia pinnata* extracts in laboratory animals, *Nig. Journ. Pharm. Sci.*, Vol.8 No. 1, 2009, Pp 102 – 108.
- [18] R. Duraisami, D. Srinivasan and S. Ramaswamy, Anticonvulsant activity of bioflavonoid gossypin, *Bangladesh Journal of Pharmacology*, (4), 2009, 51-54.
- [19] W. Loscher and D. Schmidt, Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical consideration. *Epilepsy Res.* (2), 1988, 145-81.
- [20] H. S.White, H. H. Wolf, J. H. Woodhead and H. J. Kupferberg, The national institute of health anticonvulsant drug development program: screening for efficacy. In: French, J., Leppik, I.E., and Ditcher, M.A.(Eds). *Antiepileptic drug development: Advances in Neurology*, Vol.76, (Lippincott-raven Publishers, Philadelphia, 1998) Pp. 29-39.
- [21] G. Sierra-Paredas, Recent advances in the neurochemistry of epilepsy. *Eur Neurol Rev.*, 3(1), 2008, 96–8.